Thailanstatin A fight cancer by inhibiting the spliceosome, the machinery of the cell messenger RNA editing after DNA transcription but before translation into proteins. This new anti-cancer agent, which was originally isolated from a bacterial species collected in Thailand, has been synthesized by scientists at Rice University.
‘Thailanstatin A’ – a new anti-cancer agent synthesized by Rice University Lab
synthetic chemical K. C. Nicolaou Rice and his team reported their success in Journal of the American Chemical Society .
“A new anti-cancer agent, Thailanstatin A, which was originally isolated from a bacterial species collected in Thailand has been synthesized by scientists at Rice University. “
Nicolaou and colleagues specialize in the synthesis of potential therapeutic agents that are found in nature but in quantities too small for the biological evaluation exhaustive or clinical use. He is best known for the total synthesis of paclitaxel, a drug commonly used to treat several types of cancer.
The researchers explained that the spliceosome, a complex of proteins and ribonucleoproteins which regulate DNA splicing, is more active and shows higher rates of mutation in cancer cells than in normal cells, which makes it a valid target for research .
“This cell machinery as follows mRNA edited transcription of DNA through the site specific removal of introns (non-coding DNA regions) and the remaining exon splicing (coding) sequence before translation,” Nicolaou said. “Thailanstatin A interferes with this mechanism.”
Said synthesis Thailanstatin A, first isolated from bacteria Burkholderia thailandensis, opens the way to build and test variants of the molecule. “These studies will be directed towards optimizing the pharmacological properties of this new natural product as part of a program of drug discovery and development of new therapies targeting cancer,” Nicolau said.
The program can take two directions, he said, “one directed to compounds of high power that could be used as payloads for drug conjugates of antibodies and the other to selective agents that can kill cancer cells with minimal damage to healthy cells . ”
The first paradigm is now a frontier approach for the development of targeted therapies and personalized cancer, while the second represents a more traditional approach, which could also lead to potent drugs against cancer, Nicolaou said. “Thailanstatin A exhibits only the right to be diverted to either approach through a reiterative molecular design, chemical synthesis and biological evaluation process power,” he said.
“We are very excited about this new molecule and its analogs because of their unique biological properties and perspectives working in collaboration with academic and industrial partners to advance towards them the clinic,” Nicolaou
Source :. Newswise
This article was originally published on medindia.net
Posted in: health news